AR079543A1 - Derivados de amino-heteroarilo - Google Patents

Derivados de amino-heteroarilo

Info

Publication number
AR079543A1
AR079543A1 ARP100104763A ARP100104763A AR079543A1 AR 079543 A1 AR079543 A1 AR 079543A1 AR P100104763 A ARP100104763 A AR P100104763A AR P100104763 A ARP100104763 A AR P100104763A AR 079543 A1 AR079543 A1 AR 079543A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkyloxy
halo
pain
amino
Prior art date
Application number
ARP100104763A
Other languages
English (en)
Inventor
Ronald Palin
John Kinnaird Ferguson Maclean
Angus John Morrison
Simon James Anthony Grove
Craig Jamieson
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR079543A1 publication Critical patent/AR079543A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Composiciones farmacéuticas y usos para el tratamiento del dolor. Reivindicacion 1: Un derivado de amino-heteroarilo de acuerdo con la formula general (1) caracterizado porque: Ar representa fenilo o un grupo heteroarilo de 6 miembros que contiene 1 o 2 átomos de nitrogeno, cada uno de los cuales es substituido opcionalmente con uno o más substituyentes seleccionados entre halogeno, alquilo C1-4, halo-alquilo C1-4, alquiloxi C1-4, halo-alquiloxi C1-4, CN, alquiltio C1-4 y halo-alquiltio C1-4; X es O, S o NR1; R1 es H o alquilo C1-4; R2 es alquilo C1-4, halo-alquilo C1-4, alquiloxi C1-4-alquilo C1-4 o halo-alquiloxi C1-4-alquilo C1-4; R3 es H, alquilo C1-4, halo-alquilo C1-4, alquiloxi C1-4-alquilo C1-4 o halo-alquiloxi C1-4-alquilo C1-4; o R2 y R3 forman junto con el átomo de carbono al cual están unidos un anillo saturado de 3 a 7 miembros que contiene opcionalmente un átomo de oxígeno; Y1, Y2 e Y3 son independientemente CH o N; con la condicion de que por lo menos uno de Y1, Y2 e Y3 es N y que cuando Y3 es N, Y2 es N; R4 y R5 son independientemente H, alquilo C1-4, haloalquilo C1-4, alquiloxi C1-4-alquilo C1-4; o R4 y R5 forman junto con el nitrogeno al cual están unidos un anillo saturado de 3 a 7 miembros que contiene opcionalmente un átomo de oxígeno; o una sal farmacéuticamente aceptable del mismo, para usar en el tratamiento del dolor, tal como el dolor neuropático o inflamatorio.
ARP100104763A 2009-12-22 2010-12-20 Derivados de amino-heteroarilo AR079543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09180321 2009-12-22

Publications (1)

Publication Number Publication Date
AR079543A1 true AR079543A1 (es) 2012-02-01

Family

ID=42045216

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104763A AR079543A1 (es) 2009-12-22 2010-12-20 Derivados de amino-heteroarilo

Country Status (12)

Country Link
US (1) US8952001B2 (es)
EP (1) EP2516397B1 (es)
JP (1) JP5728024B2 (es)
KR (1) KR20120095481A (es)
CN (1) CN102884048B (es)
AR (1) AR079543A1 (es)
AU (1) AU2010335231C1 (es)
BR (1) BR112012015170A8 (es)
CA (1) CA2783209C (es)
MX (1) MX2012007426A (es)
RU (1) RU2549546C2 (es)
WO (1) WO2011076723A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103442829B (zh) * 2011-05-19 2016-11-16 株式会社东芝 钼造粒粉的制造方法及钼造粒粉
SI2753606T1 (sl) 2011-09-02 2017-10-30 Purdue Pharma Lp Pirimidini kot blokatorji natrijevih kanalov
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
CN104363908B (zh) * 2012-05-30 2017-12-22 霍夫曼-拉罗奇有限公司 吡咯烷基杂环类
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606757A (en) * 1982-12-23 1986-08-19 The Dow Chemical Company Diphenoxymethylpyridines having herbicidal properties
KR100197583B1 (ko) 1997-02-04 1999-06-15 이민화 환자용모니터를 구비한 초음파진단장치
EP1297136A2 (en) 2000-05-24 2003-04-02 Akzo Nobel N.V. Full length human hcn1 ih channel subunit and variants
KR100801121B1 (ko) * 2001-04-10 2008-02-05 니뽄 신야쿠 가부시키가이샤 만성 관절 류마티즘 치료제
US6980419B2 (en) 2003-03-12 2005-12-27 Zonare Medical Systems, Inc. Portable ultrasound unit and docking station
US20090182228A1 (en) 2004-09-17 2009-07-16 Koninklijke Philips Electronics, N.V. Wireless ultrasound system display
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
DK2848610T3 (da) * 2006-11-15 2017-11-06 Ym Biosciences Australia Pty Hæmmere af kinaseaktivitet
PE20091524A1 (es) * 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
NZ602030A (en) * 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
TW201022233A (en) 2008-11-04 2010-06-16 Organon Nv (Pyrrolidin-2-yl)phenyl derivatives

Also Published As

Publication number Publication date
RU2549546C2 (ru) 2015-04-27
WO2011076723A1 (en) 2011-06-30
CA2783209C (en) 2017-03-14
AU2010335231C1 (en) 2015-04-16
RU2012131279A (ru) 2014-01-27
JP2013515031A (ja) 2013-05-02
CN102884048A (zh) 2013-01-16
US8952001B2 (en) 2015-02-10
CA2783209A1 (en) 2011-06-30
BR112012015170A2 (pt) 2016-03-29
BR112012015170A8 (pt) 2017-12-26
US20120264728A1 (en) 2012-10-18
KR20120095481A (ko) 2012-08-28
CN102884048B (zh) 2014-07-23
JP5728024B2 (ja) 2015-06-03
MX2012007426A (es) 2012-07-23
AU2010335231A1 (en) 2012-06-21
EP2516397B1 (en) 2016-07-13
AU2010335231B2 (en) 2014-09-11
EP2516397A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR064246A1 (es) Derivados de 5h-pirimido[5,4-d][2]benzazepinas inhibidores de la progresion mitotica,composiciones farmaceuticas que los contienen y usos como agentes anticancer.
PA8852101A1 (es) Nucleótidos uracil ciclopropílicos
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR084370A1 (es) Derivados de aminopirazol
AR077818A1 (es) Composiciones pesticidas
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
RU2015103515A (ru) Производное соединение сложного эфира 2-аминоникотиновой кислоты и бактерицид, содержащий то же самое в качестве активного ингредиента
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR075243A1 (es) Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
DOP2010000046A (es) Compuestos de biciclolactama sustituida
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure